Search results for "non-Hodgkin lymphoma"

showing 3 items of 33 documents

Residential Exposure to PM2.5 Components and Risk of Childhood Non-Hodgkin Lymphoma in Denmark: A Nationwide Register-Based Case-Control Study

2020

In a recent study, we observed an increased risk of childhood non-Hodgkin lymphoma (NHL) associated with exposure to fine atmospheric particulate matter (PM2.5) and black carbon (BC). In this nationwide register-based case-control study, we focus on specific components of PM2.5 in relation to childhood NHL in Denmark (1981&ndash

Register basedMale010504 meteorology & atmospheric sciencesHealth Toxicology and MutagenesisChildhood Non-Hodgkin LymphomaDenmarkSecondary organic aerosolslcsh:Medicine01 natural sciencescomplex mixturesArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineimmune system diseasesInterquartile rangehemic and lymphatic diseasesAir PollutionMedicineHumans030212 general & internal medicineChildsecondary inorganic aerosols0105 earth and related environmental sciencesAerosolsAir Pollutantsparticulate matter componentsSecondary organic aerosolsbusiness.industryLymphoma Non-Hodgkinlcsh:RPublic Health Environmental and Occupational HealthCase-control studyOdds ratiocarbonaceous particlesEnvironmental ExposureConfidence intervalCancer registryregister-based studychemistryCase-Control StudiesParticulate Matterbusinesschildhood Non-Hodgkin LymphomaDemographyEnvironmental MonitoringInternational Journal of Environmental Research and Public Health
researchProduct

Facteurs épidémiologiques influençant la survie dans le lymphome à cellules du manteau

2017

Mantle Cell Lymphoma (MCL) is a recently defined entity, typically characterised by the genetic translocation t(11 ;14)(q13 ;q32) and counting for 2 - 10% of all non-Hodgkin Lymphomas. With a median survival between 3 and 5 years after diagnosis, MCL is an agressive disease and despite the recent therapeutic advances little in know about its prognostic factors. Some studies had investigated clinicopathological features and new treatment strategies, but there is a lack of knowledge regarding the impact of lifestyle and environnemental factors on outcome of MCL patients. From 2008 to 2012, the LYSA Group conducted in France two prospective multi center clinical trials on MCL : LM manteau 2010…

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologySurvivalMantle Cell LymphomaNon-Hodgkin LymphomaPopulation-Based studyPrognostic factorsLymphome à Cellules du ManteauClinical TrialEssai CliniqueSurvieFacteurs pronosticsEtude en population généraleLymphome non-Hodgkinien[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas,

2014

Histone deacetylases (HDAC) extensively contribute to the c-Myc oncogenic program, pointing to their inhibition as an effective strategy against c-Myc-overexpressing cancers. We, thus, studied the therapeutic activity of the new-generation pan-HDAC inhibitor ITF2357 (Givinostat®) against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas (B-NHLs). ITF2357 anti-proliferative and pro-apoptotic effects were analyzed in B-NHL cell lines with c-Myc translocations (Namalwa, Raji and DOHH-2), stabilizing mutations (Raji) or post-transcriptional alterations (SU-DHL-4) in relationship to c-Myc modulation. ITF2357 significantly delayed the in vitro growth of all B-NHL cell lines by inducing G1 c…

c-MycmicroRNAnon-Hodgkin lymphomac-Myc; histone deacetylase inhibitors; microRNA; non-Hodgkin lymphomahistone deacetylase inhibitor
researchProduct